US FDA's Drug Seizures Seen As Most Significant Aspect of Stem Cell Crackdown

Executive Summary Former Office of Compliance and Biologics Quality Deputy Director Mark Schwartz says dishonest players have not often seen serious enforcement actions from the agency.

Executive Summary

Former Office of Compliance and Biologics Quality Deputy Director Mark Schwartz says dishonest players have not often seen serious enforcement actions from the agency.

Seizure of property. Yellow warning tapes with inscription
Source: pink.pharmamedtechbi.com